Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment—Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial-Reference-Cited by-同舟云学术

Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment—Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial

Published:2022-12-21 Issue:5 Volume:50 Page:1487-1498
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Kitajima Kazuhiro,Igeta Masataka,Kuyama Junpei,Kawahara Takashi,Suga Tsuyoshi,Otani Tomoaki,Sugawara Shigeyasu,Kono Yumiko,Tamaki Yukihisa,Seko-Nitta Ayumi,Ishiwata Yoshinobu,Ito Kimiteru,Toriihara Akira,Watanabe Shiro,Hosono Makoto,Miyake Hideaki,Yamamoto Shingo,Narita Mitsuhiro,Daimon Takashi,Yamakado Koichiro

Funder

PDRadiopharma, Inc

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-022-06082-3.pdf

Reference31 articles.

1. Bruland ØS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Pt 2):6250s-s6257. https://doi.org/10.1007/s00432-012-1222-2.

2. Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62(11):3120–5.

3. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. https://doi.org/10.1056/NEJMoa1213755.

4. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406. https://doi.org/10.1016/S1470-2045(14)70474-7.

5. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al; Radium-223 International Early Access Program Investigators. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306–16. https://doi.org/10.1016/S1470-2045(16)30173-5.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increase of prostate specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing [223Ra]RaCl2 therapy;2023-12-19

2. Data reconciliation connected to guard bands to set specification limits related to risk assessment for radiopharmaceutical activity;Heliyon;2023-12

3. How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology;Military Medical Research;2023-10-31

4. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial;Cancers;2023-05-16

5. The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study;Biomedicines;2023-04-05